After off-label use for 50 years, FDA oks Questcor's Acthar for infantile spasms
This article was originally published in Scrip
Executive Summary
Questcor Pharmaceuticals has gained a supplemental approval from the US FDA for its HP Acthar gel (repository corticotropin injection) as a treatment for infantile spasms, a rare form of epilepsy in infants and children under two years of age. Off-label use had taken place since 1958.